MORE

Monogram Residential Trust In

Facebook

Facebook Admitted to More Shady Dealings - Here's How to Profit

Facebook Inc.'s (Nasdaq: FB) stock tumbled 21% in March when revelations surfaced that political analytics firm Cambridge Analytica, which helped guide President Donald Trump's 2016 presidential campaign, paid for data on 87 million Facebook users without their consent.

But after a strong showing by founder and CEO Mark Zuckerberg in front of Congress to address selling of users' data in breach of a 2012 consent decree, Facebook's stock ran right back up to make new all-time highs at $203.55.

Now, in a 747-page document released to Congress last Friday, Facebook admitted giving dozens of companies special access to user data after telling Congress it restricted personal information to outsiders in 2015.

But after a strong showing by founder and CEO Mark Zuckerberg in front of Congress to address selling of users' data in breach of a 2012 consent decree, Facebook's stock ran right back up to make new all-time highs at $203.55.

Now, in a 747-page document released to Congress last Friday, Facebook admitted giving dozens of companies special access to user data after telling Congress it restricted personal information to outsiders in 2015.

Here's what Facebook's reveal could mean for the stock... and one trade that'll let you rake in mega-gains as a result...

Biotechnology

The World's First $1 Billion Cannabis Drug (and 2 More Biotech Blockbusters)

To hear Wall Street tell it, AbbVie Inc. drove right into a ditch last month.

Here's the thing. The company announced results of a Phase 2 trial on March 22 that were disappointing but hardly fatal. The results mean AbbVie won't seek fast-track approval for its promising antibody-drug conjugate, Rova-T, but it still expects to be able to take it to market in the near future.

Wall Street overreacted – no surprise there – and AbbVie shares lost 15% in three sessions.

Here's the thing. Wall Street's overreaction to AbbVie's disappointing U.S. Food and Drug Administration trial results weren't the only reason for its share-price plummet.

You see, though it shouldn't be, biotech is in the dog house – and investors are primed to punish stocks in the sector for just about anything.

But what you don't hear much about is the fact that the industry is about to bust out.

That's because biopharma companies are ready to release several potential blockbuster drugs – drugs with potential yearly sales of $1 billion – over the next few months.

I've identified three specific "Biotech Blockbusters" that could do even better than that. So, I'll show you those.

And then I'll reveal the single best way to play all three all at once...

Income Investing

Dividend-Paying Stocks: MSFT, MCD, and 22 More New Dividend Boosts

The profusion of dividend-paying stocks that have increased payouts over the last several weeks reflects a robust second-quarter earnings season.

Companies in the S&P 500 turned in 10.3% earnings growth in Q2 – the highest advance since 2011's third quarter.

Last week Microsoft (Nasdaq: MSFT), McDonald's (NYSE: MCD), and 22 other dividend stocks raised payouts. Here's the full list of dividend hikes announced during the week ending Sept. 19, 2014.

Last week Microsoft (Nasdaq: MSFT), McDonald's (NYSE: MCD), and 22 other dividend stocks raised payouts. Here's the full list of dividend hikes announced during the week ending Sept. 19, 2014.

Hot Stocks

Dividend Stocks: Big Banks Boost Payouts, Plus a Dozen More Yield Increases

Dividend stocks news:  The big dividend news last week came from the banking sector on the heels of the U.S. Federal Reserve's stress test.

The test is aimed at ensuring big banks can handle a steep slump like the 2008 financial crisis and continue operations without a government bailout. In total, 25 banks passed the central bank's test, while five failed.

To continue reading, please click here...